AbCellera Biologics Inc.

NasdaqGS:ABCL Stock Report

Market Cap: US$871.3m

AbCellera Biologics Management

Management criteria checks 4/4

AbCellera Biologics' CEO is Carl Hansen, appointed in Nov 2012, has a tenure of 12.08 years. total yearly compensation is $714.94K, comprised of 64.3% salary and 35.7% bonuses, including company stock and options. directly owns 18.89% of the company’s shares, worth $164.61M. The average tenure of the management team and the board of directors is 3.4 years and 5.3 years respectively.

Key information

Carl Hansen

Chief executive officer

US$714.9k

Total compensation

CEO salary percentage64.3%
CEO tenure12.1yrs
CEO ownership18.9%
Management average tenure3.4yrs
Board average tenure5.3yrs

Recent management updates

Recent updates

AbCellera Biologics: Still A Concept Stock

Dec 23

AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 07
AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their Estimates

AbCellera: A Platform To Pipeline Transition

Oct 14

AbCellera: A Waiting Game With High Uncertainty

Aug 23

Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth

May 29
Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth

AbCellera: Cash Providing Shelter From Market Weakness

May 16

AbCellera: Victim Of Its Own Success

Feb 28

AbCellera Biologics: Continuing To Expand Partnerships

Feb 13

Is Now The Time To Put AbCellera Biologics (NASDAQ:ABCL) On Your Watchlist?

Feb 04
Is Now The Time To Put AbCellera Biologics (NASDAQ:ABCL) On Your Watchlist?

AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Could Be 31% Below Their Intrinsic Value Estimate

Nov 29
AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Could Be 31% Below Their Intrinsic Value Estimate

AbCellera Biologics: Many Reasons To Own This Undervalued Stock

Sep 06

AbCellera Biologics: COVID Antibody Set To Provide Continued Funding

Aug 14

AbCellera partnering with Atlas Ventures on development of therapeutic antibodies

Aug 03

AbCellera Biologics: Fully Funded, With New Opportunities And Massive Insider Buying

Jun 06

Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)

May 13
Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)

Not Many Are Piling Into AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Yet As It Plummets 25%

May 07
Not Many Are Piling Into AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Yet As It Plummets 25%

AbCellera Biologics: Potentially Bottoming Out Amidst Terrible Market Sentiment

Apr 22

AbCellera Biologics: Bebtelovimab Supply Deal Provides A Much Needed Shot In The Arm

Feb 11

CEO Compensation Analysis

How has Carl Hansen's remuneration changed compared to AbCellera Biologics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$176m

Jun 30 2024n/an/a

-US$153m

Mar 31 2024n/an/a

-US$147m

Dec 31 2023US$715kUS$460k

-US$146m

Sep 30 2023n/an/a

-US$129m

Jun 30 2023n/an/a

-US$74m

Mar 31 2023n/an/a

-US$50m

Dec 31 2022US$9mUS$450k

US$159m

Sep 30 2022n/an/a

US$248m

Jun 30 2022n/an/a

US$200m

Mar 31 2022n/an/a

US$205m

Dec 31 2021US$9mUS$400k

US$153m

Sep 30 2021n/an/a

US$177m

Jun 30 2021n/an/a

US$197m

Mar 31 2021n/an/a

US$203m

Dec 31 2020US$17mUS$296k

US$85m

Sep 30 2020n/an/a

-US$285k

Jun 30 2020n/an/a

US$2m

Mar 31 2020n/an/a

-US$3m

Dec 31 2019US$250kUS$177k

-US$2m

Compensation vs Market: Carl's total compensation ($USD714.94K) is below average for companies of similar size in the US market ($USD3.22M).

Compensation vs Earnings: Carl's compensation has been consistent with company performance over the past year.

CEO

Carl Hansen (50 yo)

12.1yrs

Tenure

US$714,939

Compensation

Dr. Carl L. G. Hansen, Ph.D. is a Co-Founder of AbCellera Biologics Inc. and has been its Chief Executive Officer and Director since November 2012 and serves as its Chairperson. Dr. Hansen serves as a Memb...

Leadership Team

NamePositionTenureCompensationOwnership
Carl Hansen
CEO, President & Chairperson12.1yrsUS$714.94k18.89%
$ 164.6m
Andrew Booth
Chief Financial Officer5.3yrsUS$674.56k0.096%
$ 837.7k
Veronique Lecault
COO & Director5.9yrsUS$650.59k3.25%
$ 28.4m
Tryn Stimart
Chief Legal Officer5.3yrsUS$667.69k0.00017%
$ 1.5k
Marcie Thiessen
Senior Director of Finance & Accountingno datano datano data
Ester Falconer
Chief Technology Officer3.9yrsno datano data
Graham Craig
Director of Corporate Development1.9yrsno datano data
Murray McCutcheon
Senior Vice President of Partnering1.9yrsno datano data
Neil Aubuchon
Chief Commercial Officer2.9yrsUS$5.61m0.016%
$ 142.8k
Adam Clarke
Senior Vice President of Discoveryno datano datano data
Paul Colussi
Site Head & VP of Complex Membrane Protein Technologies1.9yrsno datano data
Janna Bednenko
Head of Protein Expression & Genetics1.9yrsno datano data

3.4yrs

Average Tenure

50.5yo

Average Age

Experienced Management: ABCL's management team is considered experienced (3.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Carl Hansen
CEO, President & Chairperson12.1yrsUS$714.94k18.89%
$ 164.6m
Veronique Lecault
COO & Director6.3yrsUS$650.59k3.25%
$ 28.4m
Michael Hayden
Independent Lead Director5.3yrsUS$105.00k0.49%
$ 4.3m
John Montalbano
Independent Non-Employee Director4.1yrsUS$77.50k0.031%
$ 268.5k
Wen-Chaun Lo
Independent Director3yrsUS$55.00k0%
$ 0

5.3yrs

Average Tenure

59yo

Average Age

Experienced Board: ABCL's board of directors are considered experienced (5.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 01:16
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AbCellera Biologics Inc. is covered by 17 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert WassermanBenchmark Company
Antonia BorovinaBloom Burton & Co.
David MartinBloom Burton & Co.